Skip to main content

Advertisement

SpringerLink
Log in

Considerations for the management of urgency symptoms in patients with overactive bladder syndrome

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Traditionally, urinary frequency and/or urgency incontinence have been the primary outcome measurements for the symptom complex of overactive bladder (OAB). However, urgency, by definition, precedes urgency incontinence, and drives frequency and nocturia in OAB and should be considered in this pivotal role.

Materials and methods

Review of published literature on this topic.

Results

The management of urgency is evolving as of major clinical importance to patients. Recent use of diary-based urgency metrics has advanced our knowledge of the presence and nature of urgency symptoms, the impact on QoL and the response to treatment options.

Conclusion

It is logical that the management of the number of urgency episodes and the degree of urgency, as well as the impact and bother associated with this core symptom are all taken into consideration along with patient interpretation to facilitate an effective outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abrams P (2005) Urgency: the key to defining the overactive bladder. BJU Int 96(Suppl 1):1–3

    Article  PubMed  Google Scholar 

  2. Hung MJ, Ho E, Shen P-S, Sun M-J, Lin A, Chen G-D (2006) Urgency is the core symptom of female overactive bladder syndrome as demonstrated by statistical analysis. J Urol 176:636–640

    Article  PubMed  Google Scholar 

  3. Homma Y (2008) Lower urinary tract symptomatology: its definition and confusion. Int J Urol 15:35–43

    PubMed  Google Scholar 

  4. Donaldson MMK, Thompson JR, Matthews RJ, Dallosso HM, McGrother CW (2006) The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3 year prospective cohort study. Neurourol Urodyn 25:709–716

    Article  CAS  PubMed  Google Scholar 

  5. Heidler S, Deveza C, Temml C, Ponholzer A, Marszalek M, Berger I, Bluhm A, Madersbacher S (2007) The natural history of lower urinary tract symptoms in females: analysis of a health screening project. Euro Urol 52:1744–1750

    Article  Google Scholar 

  6. Møller LA, Lose G, Jørgensen T (2000) Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40–60: longitudinal study. Br Med J 320:1429–1432

    Article  Google Scholar 

  7. Wennberg A, Molander U, Fall M, Edlund E, Peeker R, Milsom I (2009) A Longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol doi:10.1016/j.eururo.2009.01.007

  8. Abrams P, Blaivas JG, Stanton S, Andersen JT (1988) ICS standardisation of terminology of lower urinary tract function. Neurourol Urodyn 7:403–426

    Article  Google Scholar 

  9. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmstein U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub committee of the international continence society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  10. Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99:101–106

    Article  CAS  PubMed  Google Scholar 

  11. Cardozo L, Dewilde T, Feyereisl J, Wadie B, Amarenco G, Liapis A, Drogendijk T, Wright M, Bolodeoku J (2006) Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study. Neurol Urodyn 25(6) (abstract 281)

  12. Serels S, Andoh M, Smith N (2006) Solifenacin significantly improves urgency in overactive bladder (OAB) patients compared to placebo. Urology 68 (Suppl 5a):72 MP-04.11

  13. Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski U, Staskin D, Zinner N (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607

    Article  PubMed  Google Scholar 

  14. Rudy D, Cline K, Goldberg K, Harris R (2004) A multicenter, randomized, placebo controlled trial of trospium chloride in overactive bladder patients. ICS and IUGA (Paris, France) (abstract 144)

  15. Zinner N, Harnett M, Sabounjian L, Sandage B, Dmochowski R, Staskin D (2005) The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 173:1639–1643

    Article  PubMed  Google Scholar 

  16. Andersson K-E, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J, Nishizawa O, Vela Navarette R, Wein A (2005) In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Third international consultation in incontinence, Monaco, 26–29 June 2005, Chap 14. Health Publications Ltd.

  17. http://www.urotoday.com/287/conference_coverage/ici_2008/2757/

  18. National Institute for Health and Clinical Excellence (2006) Urinary incontinence: the management of urinary incontinence in women, vol 40. NICE Clinical Guideline. http://www.nice.org.uk/CG040

  19. Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48:5–26

    Article  CAS  PubMed  Google Scholar 

  20. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD003781

    Google Scholar 

  21. Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68(Suppl 2):38–48

    Article  PubMed  Google Scholar 

  22. Alhasso AA, McKinlay J, Patrick K, Stewart L (2008) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2:CD003193

  23. Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562

    Article  CAS  PubMed  Google Scholar 

  24. Song C, Park JT, Heo KO, Lee KS, Choo M-S (2006) Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 21:1060–1063

    Article  CAS  PubMed  Google Scholar 

  25. Mattiasson A, Blaakaer J, Høye K, Wein AJ (2003) Tolterodine Scandanavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91(1):54–60

    Article  CAS  PubMed  Google Scholar 

  26. Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager CW, Kenton K, Tennstedt SL, Kusek JW, Debuene Chang T, Nyberg LM, Steers W for the Urinary Incontinence Treatment Network. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment. Ann Intern Med 2008;149(3):161–169

    Google Scholar 

  27. Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G (2008) DelConte: a comparison of the efficacy of darifenacin alone vs darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder. Int J Clin Pract 62(4):606–613

    Article  CAS  PubMed  Google Scholar 

  28. Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326:841–844

    Article  CAS  PubMed  Google Scholar 

  29. Morris AR, Westbrook JI, Moore KH (2008) A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity. BJOG 115:239–246

    Article  CAS  PubMed  Google Scholar 

  30. Cardozo LD, Heβdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomised, double-blind, placebo-controlled, rising-dose trial. BJU Int 102(9):1120–1127

    Article  CAS  PubMed  Google Scholar 

  31. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder. Results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73 (1):14–8 (Epub 2008 Nov 8)

    Google Scholar 

  32. Serels S, Andoh M, Smith N (2006) Solifenacin treatment in patients with OAB reduces symptom bother and improves health-related quality of life. Urology 68 (suppl 5a):73 MP-04.15

  33. Cardozo L, Nagy G, Kiss L, Al-Shukri S, Mikulas J, Svihra J, Drogendijk T, Wright M, Bolodeoku J (2006) Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int Urogyn J 17(Supp 2) (abstract 052)

  34. Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R (2008) Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 24(6):1583–1591

    Article  CAS  PubMed  Google Scholar 

  35. Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once daily treatment for overactive bladder. Eur Urol 45:420–429

    Article  CAS  PubMed  Google Scholar 

  36. Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutinin in the treatment of patients with overactive bladder. World J Urol 23:248–252

    Article  CAS  PubMed  Google Scholar 

  37. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z (2008) Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 71(5):839–843 (Epub 17 Mar 2008)

    Article  PubMed  Google Scholar 

  38. Chapple CR, Rechberger T, Al-Shukri A, Meffan P, Everaert K, Huang M, Ridder A on behalf of the YM-905 study group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solofenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310

    Google Scholar 

  39. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470

    CAS  PubMed  Google Scholar 

  40. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924

    Article  CAS  PubMed  Google Scholar 

  41. Zinner N, Mattiason A, Stanton S (2002) Efficacy, safety and tolerability of extended release once daily tolterodine treatment for overactive in older versus younger patients. JAGS 50(5):709–807

    Article  Google Scholar 

  42. Dmochowski RR, Sand PK, Zinner NR, Staskin DR (2008) Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 71:449–454

    Article  PubMed  Google Scholar 

  43. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Höfner K (2003) Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20:392–399 (Epub 2003 Mar 28)

    CAS  PubMed  Google Scholar 

  44. Staskin D, Sand P, Zinner N (2007) Dmochowski for the trospium study group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 178:978–984

    Article  CAS  PubMed  Google Scholar 

  45. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S (2004) Trospium study group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171(6 pt 1):2311–2315

    Article  CAS  PubMed  Google Scholar 

  46. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutinin in patients with urgency and urge incontinence. BJU Int 84:646–651

    Article  CAS  PubMed  Google Scholar 

  47. Michel MC, de la Rosette JJ (2005) Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 96(Suppl 1):37–42

    Article  CAS  PubMed  Google Scholar 

  48. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F (2006) Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist an investigation of warning time in patients with OAB. Int J Clin Pract 60(1):119–126

    Article  CAS  PubMed  Google Scholar 

  49. Cardozo L, Dixon A (2005) Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 173:1214–1218

    Article  PubMed  Google Scholar 

  50. Swithinbank L, Abrams P, Hashim H (2005) The effect of fluid intake on urinary symptoms in women. Curr Opin Urol 174:187–189

    CAS  Google Scholar 

  51. Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS (2005) Weight loss: a novel and effective treatment for urinary incontinence. J Urol 174(1):190–195

    Article  PubMed  Google Scholar 

  52. Wang A, Chih S, Chen M (2006) Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology 68(5):999–1004

    Article  PubMed  Google Scholar 

  53. Jarvis GJ, Millar DR (1980) Controlled trial of bladder drill for detrusor instability. BMJ 281(6251):1322–1323

    Article  CAS  PubMed  Google Scholar 

  54. Majumdar (Personal communication) Inpatient bladder retraining (IBR): an evaluation of services in a tertiary referral centre (Majumdar A, Toozs-Hobson P, Parsons M, Hassan I, Robb K)

  55. Wilson PD, Berghmans B, Hagen S, Hay-Smith J, Moore K, Nygaard I, Sinclair L, Yamanishi T, Wyman J, Dorey G (2005) In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Third international consultation in incontinence, Monaco, 26–29 June 2005, Chap 15. Health Publications Ltd.

  56. Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd LK (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women. JAMA 288(10):2293–2299

    Article  PubMed  Google Scholar 

  57. Roe B, Milne J, Ostaszkiewicz J, Wallace S (2007) Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings on theory and methods using metastudy techniques. J Adv Nurs 57(1):3–14

    Article  PubMed  Google Scholar 

  58. Eriksen PS, Rasmussen H (1992) Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 44:137–144

    Article  CAS  PubMed  Google Scholar 

  59. Cardozo LD, Wise BG, Benness CJ (2001) Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women: a double-blind placebo-controlled study. J Obstet Gynaecol 21:383–385

    Article  CAS  PubMed  Google Scholar 

  60. Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, Lin F, Brown JS (2005) Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol 106:940–945

    CAS  PubMed  Google Scholar 

  61. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, Aragaki A, Naughton MJ, Wallace RB, McNeeley SG (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948

    Article  CAS  PubMed  Google Scholar 

  62. Braun PM, Seif C, van der Horst C, Junemann K-P (2004) Neuromodulation-sacral, peripheral and central: current status, indications, results and new developments. EAU Update Ser 2:187–194

    Article  Google Scholar 

  63. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177–185

    Article  CAS  PubMed  Google Scholar 

  64. Schurch B (2006) Botulinum toxin for the management of bladder dysfunction. Drugs 66:1301–1318

    Article  CAS  PubMed  Google Scholar 

  65. Silva C, Silva J, Castro H, Reis F, Dinis P, Avelino A, Cruz F (2007) Bladder sensory desensitization decreases urinary urgency. BMC Urol 7:9

    Article  PubMed  Google Scholar 

  66. Robinson D, Anders K, Cardozo L, Bidmead J, Dixon A, Balmfoth J, Rufford J (2003) What do women want? Interpretation of the concept of cure. J Pelvic Med Surg 9(6):273–277

    Article  Google Scholar 

Download references

Conflict of interest statement

During the last year LC has worked with the following companies as a lecturer, advisor or researcher; Astellas, Pfizer, Allergan, Bioxell, Rottapharm, Schering Plough. DS is a consultant for Allergan, Astellas, Pfizer, Watson. PVK has no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Urogynaecology, King’s College Hospital, London, SE5 9RS, UK

    Linda D. Cardozo

  2. 8 Devonshire Place, London, W1G 6HP, UK

    Linda D. Cardozo

  3. Department of Urology, University Hospital, Maastricht, The Netherlands

    Philip E. V. A. Van Kerrebroeck

  4. Department of Urology, Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA

    David R. Staskin

Authors
  1. Linda D. Cardozo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip E. V. A. Van Kerrebroeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David R. Staskin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda D. Cardozo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cardozo, L.D., Van Kerrebroeck, P.E.V.A. & Staskin, D.R. Considerations for the management of urgency symptoms in patients with overactive bladder syndrome. World J Urol 27, 755–763 (2009). https://doi.org/10.1007/s00345-009-0455-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0455-4

Keywords

Search

Navigation